Tamoxifen and Raloxifene Exhibit Different Effects on Estrogen Receptor Expression and Cell Proliferation

Researchers at the Medical University of Bialystok, Poland, have discovered that tamoxifen and raloxifene, two commonly used medications in clinical practice, have distinct effects on estrogen receptor expression and cell proliferation in the human endometrial adenocarcinoma cell line. The study found that tamoxifen increases the risk of developing endometrial cancer by altering the ERalpha/ERbeta ratio and increasing Ki-67 antigen expression, while raloxifene has no effect on ERbeta expression and does not increase cell proliferation. These findings suggest that tamoxifen may be more carcinogenic than raloxifene, and that further research is needed to understand the mechanisms behind these differences.

Key Takeaways:

• Tamoxifen increases the risk of developing endometrial cancer by altering the ERalpha/ERbeta ratio and increasing Ki-67 antigen expression.
• Raloxifene has no effect on ERbeta expression and does not increase cell proliferation.
• The study used immunohistochemical techniques to analyze the effects of tamoxifen and raloxifene on estrogen receptors and Ki-67 antigen expression.
• All concentrations of tamoxifen (0.1 nM, 1 nM, 10 nM, 1 microM, 10 microM, and 20 microM) and raloxifene (0.1 nM, 1 nM, 10 nM, 1 microM, 10 microM, and 20 microM) had no effect on Erbeta expression.
• Tamoxifen increased Ki-67 antigen expression in the Ishikawa cell line, indicating increased cell proliferation.
• The study was published in Oncology Reports (Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line).

Statistics:

• 10 microM and 20 microM concentrations of tamoxifen resulted in increased ERalpha expression, but no effect on ERbeta.
• 0.1 nM, 1 nM, 10 nM, 1 microM, 10 microM, and 20 microM concentrations of raloxifene had no effect on expression of Erbeta.
• The study found a significant increase in Ki-67 antigen expression in the Ishikawa cell line after treatment with tamoxifen.
• 517-521: The range of page numbers where the study was published in Oncology Reports.

Sources:

• Koda, M., et al. "Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line." Oncol Rep 12.3 (2004): 517-521.
• S. Wolczynski, Med University of Bialystok, Dept. of Gynecology Endocrinol, Clinical Gynecology, Sklodowskiej 24A, PL-15276 Bialystok, Poland.
• Professor D a Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece.